ArticleLaboratory animal research2025
Evaluation of the protective effects of Spirulina platensis against cyclophosphamide-induced genotoxicity.
Article in Laboratory animal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDamage to normal cells is the most common limitation of cancer chemotherapy. Cyclophosphamide, one of the most widely used anticancer drugs due to its cytotoxicity, can bind to deoxyribonucleic acid (DNA), causing chromosomal breaks, micronuclei, and cell death. The use of natural sources helps to prevent this damage, and Spirulina platensis is highly appreciated for its numerous bioactive compounds. This study aimed to investigate the antigenotoxic effects of Spirulina platensis powder (PoSP) on mouse bone marrow cells in vivo via a micronucleus assay.
resultsCompared to the positive control, the administration of powder significantly reduced the PCE/PCE + NCE (polychromatic erythrocytes, normochromatic erythrocytes) ratio in treated mice. A significant increase in the percentage of MnPCE (micronucleus in polychromatic erythrocytes) in cyclophosphamide-treated bone marrow cells was observed. Compared with the positive controls, the groups treated with different doses in combination with cyclophosphamide presented a significant (p<0.0001) decrease in MnPCE in a dose-dependent manner. Compared to the positive control, PoSP significantly decreased MDA (malondialdehyde) levels in the livers of treated animals. The same things were observed in the kidneys and spleen. The catalase activity was also significantly increased in tissues, compared to negative control.
conclusionsThese findings suggest that PoSP does not cause DNA damage and can prevent genotoxicity, probably through its antioxidant activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.